Navigation Links
Cornerstone Therapeutics' David Price Named 2009 Chief Financial Officer of the Year by the Triangle Business Journal
Date:7/20/2009

CARY, N.C., July 20 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing products primarily for the respiratory and related markets, announced today that David Price, Executive Vice President, Finance, and Chief Financial Officer, has been named Triangle Business Journal's CFO of the Year in the Small Public Business category. Award recipients were recognized at the inaugural Triangle Business Journal's CFO of the Year Awards Luncheon held in Cary on July 14, 2009.

"David is very deserving of this award and we congratulate him on this honor," said Cornerstone's President and CEO, Craig Collard. "Cornerstone has achieved tremendous growth in recent months and David has played a critical role in shaping the direction of the Company. He has displayed a level of commitment and financial leadership unmatched by most."

Mr. Price joined Cornerstone Therapeutics as Executive Vice President, Finance, and Chief Financial Officer, in September 2008, just prior to the completion of the reverse merger between Critical Therapeutics, Inc. and Cornerstone BioPharma, Inc., a transaction he helped facilitate as managing director at Jefferies & Company, Inc. In addition, Mr. Price was instrumental in finalizing Cornerstone's recently announced agreement with Chiesi Farmaceutici, SpA, a leading European pharmaceutical company headquartered in Parma, Italy, that resulted in a $70 million transaction and Cornerstone's receipt of an exclusive 10-year license for the U.S. commercial rights to Curosurf(R), the world leading treatment approved by the U.S. Food and Drug Administration for Respiratory Distress Syndrome in premature infants.

Mr. Price has more than 25 years of international experience working for leading accounting and investment firms, including Jefferies & Company, Bear, Stearns & Co. and Price Waterhouse, as well as with Cornerstone Therapeutics. He holds an Honors degree in Accounting and Financial Management from Lancaster University in Lancaster, UK. Mr. Price is a Qualified Charter Accountant and a member of the Institute of Chartered Accountants in England and Wales.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Curosurf(R) is a registered trademark of Chiesi Farmaceutici, SpA.


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product
2. Cornerstone Therapeutics Joins the Russell 3000(R) Index
3. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Issuance and Sale of Stock
4. TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform
5. Cornerstone Therapeutics Announces Management Change
6. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
7. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
8. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
9. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
10. Cornerstone Therapeutics Announces New Board of Directors
11. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health ... Distinction, recognizing the organization as a top behavioral service provider in the country. ... clinical quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation ... research and development, largely due to its potential for revolutionizing human disease treatment. ... and human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... EHS audit protocols to understand the scope of their EHS regulatory obligations and ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
(Date:12/5/2016)... According to a new market research report "Cartilage Repair/ Cartilage ... Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - Forecast ... USD 779.8 Million by 2021 from USD 414.6 Million in 2016, ... 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology: